Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2020 Aug 26;14(8):e0008493. doi: 10.1371/journal.pntd.0008493

Emerging Cryptococcus gattii species complex infections in Guangxi, southern China

Chunyang Huang 1,#, Clement K M Tsui 2,3,4,#, Min Chen 5, Kaisu Pan 1, Xiuying Li 1, Linqi Wang 6, Meini Chen 7, Yanqing Zheng 1, Dongyan Zheng 1, Xingchun Chen 8, Li Jiang 1, Lili Wei 1, Wanqing Liao 5,*, Cunwei Cao 1,*
Editor: Nelesh Premapragasan Govender9
PMCID: PMC7449396  PMID: 32845884

Abstract

The emergence and spread of cryptococcosis caused by the Cryptococcus gattii species complex has become a major public concern worldwide. C. deuterogattii (VGIIa) outbreaks in the Pacific Northwest region demonstrate the expansion of this fungal infection to temperate climate regions. However, infections due to the C. gattii species complex in China have rarely been reported. In this study, we studied eleven clinical strains of the C. gattii species complex isolated from Guangxi, southern China. The genetic identity and variability of these isolates were analyzed via multi-locus sequence typing (MLST), and the phylogenetic relationships among these isolates and global isolates were evaluated. The mating type, physiological features and antifungal susceptibilities of these isolates were also characterized. Among the eleven isolates, six belonged to C. deuterogattii, while five belonged to C. gattii sensu stricto. The C. deuterogattii strains from Guangxi, southern China were genetically variable and clustered with different clinical isolates from Brazil. All strains were MATα, and three C. deuterogattii isolates (GX0104, GX0105 and GX0147) were able to undergo sexual reproduction. Moreover, most strains had capsule and were capable of melanin production when compared to the outbreak strain from Canada. Most isolates were susceptible to antifungal drugs; yet one of eleven immunocompetent patients died of cryptococcal meningitis caused by C. deuterogattii (GX0147). Our study indicated that the highly pathogenic C. deuterogattii may be emerging in southern China, and effective nationwide surveillance of C. gattii species complex infection is necessary.

Author summary

Cryptococcosis is a fatal systemic fungal disease caused by Cryptococcus neoformans/gattii species complexes. As a former member of the C. neoformans, C. gattii had been easily neglected before being elevated to species level. Human C. gattii species complex infection was previously confined to the tropical and subtropical regions worldwide. However, in 1999, an outbreak of C. gattii species complex occurred on Vancouver Island in Canada then expanded to the Pacific Northwest in the USA, causing over 200 infections. The highly virulent, highly pathogenic and more resistant to antifungal drugs of this species have become a therapeutic problem. To initiate a better understanding of the infection characteristics and pathogenicity of C. gattii species complex in Guangxi, southern China, the current study aimed to characterize the C. gattii species complex isolates genetically and phenotypically. The ISHAM consensus MLST scheme was utilized to investigate the genetic structure of C. gattii species complex and to correlate their geographic origin, clinical source, virulence factors and antifungal susceptibility. The authors expect that this work can support surveillance and encourage more research and public health initiatives to prevent and control the cryptococcosis cause by C. gattii species complex.

Introduction

Cryptococcus is a life-threatening fungal pathogen of humans and animals[1]. The infection process of Cryptococcus is usually via the inhalation of airborne spores (or yeast cells) into the respiratory tract and their subsequent dissemination to the central nervous system, causing pulmonary cryptococcosis and cryptococcal meningoencephalitis[1, 2]. During the past two decades, considerable genetic heterogeneity has been demonstrated to occur in the C. neoformans/gattii species complexes by a plethora of molecular methods. Various molecular biological techniques have been used to study the epidemiology and population structure of the Cryptococcus gattii/neoformans species complexes, including random amplification of polymorphic DNA (RAPD) analysis, PCR fingerprinting, amplified fragment length polymorphism (AFLP) analysis, multilocus microsatellite typing (MLMT) analysis and multi-locus sequence typing (MLST) analysis[3]. Recently, next-generation sequencing (NGS) technology has been utilized to investigate the epidemiology of C. gattii isolates[4]. However, the identification of the species is commonly based on the MLST protocol standardized by the International Society for Human and Animal Mycology (ISHAM)[5]. The MLST scheme has become an important tool for the characterization of the population genetic structure of the Cryptococcus species. Since the taxonomy of the polyphyletic genus Cryptococcus has been thoroughly revised, two varieties of C. neoformans have been recognized as species: C. neoformans (formerly C. neoformans variety grubii) and C. deneoformans (formerly C. neoformans variety neoformans)[68]. However, the molecular types of C. gattii species complex have been elevated to the species level as C. gattii sensu stricto (AFLP4/VGI), C. deuterogattii (AFLP6/VGII), C. bacillisporus (AFLP5/VGIII), C. tetragattii (AFLP7/VGIV) and C. decagattii (AFLP10/VGIV)[7]. The C. deuterogattii subtype (AFLP6A/VGIIa, AFLP6B/VGIIb and AFLP6C/VGIIc) caused an outbreak in the Pacific Northwest (PNW) region of Canada and the United States[9, 10].

Cryptococcosis is a global and invasive systematic mycosis caused by C. gattii/neoformans species complexes, leading to morbidity and mortality in both immunocompetent and immunocompromised individuals, such as those with acquired immune deficiency syndrome (AIDS) or those undergoing organ transplantation[11]. Infections due to C. neoformans species complex occur worldwide while cryptococcosis caused by C. gattii species complex was traditionally considered an endemic disease, and associated with tropical and subtropical climates[11]. However, the outbreaks of C. deuterogattii in humans and a wide range of mammals in Vancouver Island and the PNW of the USA demonstrates that the fungus has adapted to environments beyond the endemic (sub)tropical regions[9, 10]. The source of infection is usually traced back to Eucalyptus and other species of trees, such as Ficus spp. and Terminalia spp. (almond) trees[12, 13].

In Asia, the first case of C. gattii species complex infection was reported by Wanqing Liao in 1980 by the strain formerly named as S8012 and now identified as C. gattii s.s.[14]. C. gattii s.s. is the most frequently encountered species worldwide[3], and only a few sporadic cases of C. deuterogattii infection have been reported in Asian countries such as India, Thailand, and Malaysia[15]. In 2007, Okamoto et al. reported the first case of cryptococcosis caused by a highly virulent C. deuterogattii subgenotype (AFLP6A/VGIIa) in Japan[16]. However, to our knowledge, reports of C. gattii species complex infection in China are limited. A study in 2008 showed that nine of 115 (7.8%) clinical Cryptococcus isolates were members of the C. gattii species complex, consisting of eight strains of C. gattii s.s. and one strain of C. deuterogattii[17]. Several sporadic C. deuterogattii infections have also been reported in mainland China, mainly in southern China[18, 19]. However, the genetic identity and variability of these isolates and the phylogenetic relationships among these clinical isolates and global isolates have yet to be thoroughly investigated.

In this study, we described eleven cases of cryptococcosis caused by C. gattii species complex infections between 2014 and 2018 in Guangxi, southern China. We determined their genotypes by MLST and studied their phylogenetic relationships with the global strains. We also characterized the mating type, physiological characteristics, virulence factors and antifungal susceptibility of these clinical isolates.

Materials and methods

Ethics statement

This study was approved by the Medical Ethics Committee of First Affiliated Hospital of Guangxi Medical University. All participants were adults. The clinical data in this study was obtained with the written consent of the patient or the patient’s family and data collected concerning them was anonymized.

Selection of C. gattii species complex from clinical isolates

To study the epidemiological characteristics of cryptococcosis caused by C. gattii species complex in Guangxi, southern China, all the clinical strains of Cryptococcus spp. stored in the Fungal Diseases Survey Center of Guangxi, the First Affiliated Hospital of Guangxi Medical University Guangxi, southern China, have been evaluated. In total, one hundred and twenty Cryptococcus strains were isolated from patients with clinically confirmed cryptococcosis between 2014 and 2018. All but three were isolated from the patients hospitalized in First Affiliated Hospital of Guangxi Medical University, which is the largest tertiary care hospital in the Guangxi Autonomous Region in southern China and has 2750 beds. Two strains were from The Fourth People's Hospital of Nanning and one strain was from the People's Hospital of Guangxi Zhuang Autonomous Region. Among the 120 strains, most of them were from incident patients, except one (GX0049) was a relapse patient. Six strains isolated from the bronchoalveolar lavage fluid (BALF), three from lung tissue and two from skin tissue; the other strains isolated from CSF. The data of the patients was collected using a standardized form that was based entirely on the medical reports of each patient, including demographic information (age and gender), domiciles, birth and development details, medical history, clinical manifestations, laboratory data, imaging changes, diagnoses, treatments, and prognoses.

All strains were subcultured on Sabouraud Dextrose Agar (SDA) plates and incubated at 25°C, and then transferred onto L-Canavanine-glycine-bromothymol blue (CGB) medium for three to seven days to differentiate C. neoformans from C. gattii species complex as previously described [20]. In the CGB medium, eleven isolates had a positive reaction and turned the medium blue, while the rest of isolates failed to produce a color change, which were further identified as C. neoformans var. grubii by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Among the eleven strains of C. gattii species complex, ten strains were isolated from CSF, and one strain was isolated from lung tissue.

Reference Cryptococcus strains R265 (AFLP6A/VGIIa) and H99 (AFLP1/VNI) were acquired from Shanghai Key Laboratory of Molecular Medical Mycology, Changzheng Hospital, Second Military Medical University, Shanghai, China. MATa strains (AFLP2/VNIV, AFLP1/VNI and AFLP6/VGII) were obtained from State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

MLST and phylogenetic analysis

Isolates were cultured on SDA for 72 h prior to DNA extraction. Genomic DNA was extracted with the NuClean Plant Genomic DNA Kit (CWBIO, Beijing, China). Based on the ISHAM consensus MLST scheme, seven loci including capsule polysaccharide (CAP59), glycerol 3-phosphate dehydrogenase, (GPD1), laccase (LAC1), the intergenic spacer (IGS1) region, phospholipase B1 (PLB1), superoxide dismutase (SOD1), and orotidine monophosphate pyrophosphorylase (URA5) genes were amplified and sequenced[5]. The alleles were analyzed, and the STs were determined based on the MLST database (http://mlst.mycologylab.org). The sequences of the seven MLST loci have been deposited in the MLST database and GenBank.

Phylogenetic analysis of the C. gattii species complex was performed based on the alignment of seven concatenated nucleotide sequences (CAP59, GPD1, LAC1, IGS1, PLB1, SOD1 and URA5)[21]. The genetic relationships among these Chinese clinical strains and strains in different countries[2123] were investigated by MEGA7[24]; a phylogenetic tree was generated using the maximum likelihood method with a bootstrap analysis using 1000 replicates[2426]. Principal component analysis (PCA) was performed with the Adegenet 2.1.1 package for software R (version 3.4.4) to explore the genetic relationships and geographic patterns of the strains[27].

Mating type determination and physiological analysis

Mating types were determined by using specific primers targeting the MFα and MFa pheromone genes as previously described[28]. Mating experiments were performed by pairing eleven clinical strains and two reference strains (MATα; AFLP6A/VGIIa R265 and AFLP1/VNI H99) with three strains of the opposite mating type (MATa; AFLP2/VNIV, AFLP1/VNI and AFLP6/VGII) on V8 medium at 25°C in darkness for two weeks. The experiment was carried out twice, and the formation of hyphae and sexual structures was observed and investigated under a microscope.

Since certain strains were able to mate in vitro, we also studied and compared their virulence factors to the standard reference strain (R265). Melanin production, and capsule formation were evaluated using slightly modified protocols that were published previously[2931]. Visual analysis of melanin production was performed on caffeic acid agar; strains were grown on agar plates incubated at 30°C and 37°C for 72 h and observed the appearance of brown yeast colonies. Capsule formation was induced with RPMI-1640 medium for 72 h at 37°C and 5% CO2. The capsule size of at least 100 cells was quantified by light microscopy using encapsulated to naked yeast size (cell wall to cell wall diameter) ratios.

Antifungal susceptibility testing

Antifungal agents fluconazole (FLC), fluorocytosine (5FC), amphotericin B (AMB), itraconazole (ITC), voriconazole (VOR), posaconazole (POS) and isavuconazole (ISA) were used in the susceptibility tests. The broth microdilution method was performed following the CLSI M27-A3 guidelines[32] to assess the antifungal susceptibility of all clinical isolates in vitro. The concentration ranges were 0.125–64 μg/mL for FLC, 0.008–4 μg/mL for 5FC, 0.016–8 μg/mL for AMB and 0.002–1 μg/mL for ITC, VOR, POS and ISA. The MIC values were recorded after incubation at 37°C for 72 h. The MIC of AMB was defined as the lowest concentration of drug showing no yeast growth, while the MICs for other antifungal agents were defined as low drug concentrations that caused a prominent reduction in growth (≥50%) compared with the drug-free growth control. Since there was no established breakpoints standard of antifungal drugs for Cryptococcus, therefore, epidemiological cutoff values (ECVs) has been offered to determine whether a strain is wild type (in vitro susceptible) or non-wild type (in vitro resistant). Based on the previous recommendation[3335], the ECVs of C. gattii s.s. for FLC were 8 μg/mL; 4 μg/mL for 5FC; 0.5 μg/mL for AMB, ITC, VOR and POS; and 0.25 μg/mL for ISA. The ECVs of C. deuterogattii were 32 μg/mL for FLC; 16 μg/mL for 5FC; 1 μg/mL for AMB; 0.5 μg/mL for ITC and POS; and 0.25 μg/mL for VOR and ISA[3335]. Candida parapsilosis ATCC22019 was used for quality control strain.

Statistical analysis

Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). The p values of the relative capsule size data were calculated using one-way ANOVA statistical analysis. p < 0.05 was considered statistically significant.

Accession numbers

MLST nucleotide sequences for the eleven clinical isolates determined in this study have been deposited in the GenBank nucleotide sequence database under accession numbers

MK344035-MK344111.

Results

Clinical characteristics of C. gattii species complex cases

The clinical manifestations and medical histories of the 11 patients are summarized in Table 1. A total of ten cryptococcal meningitis (CM) patients and one pulmonary cryptococcosis (PC) patients were enrolled. The population included eight males and three females, with a mean age of 38.0±7.8 years (range 29–54 years). Among ten CM patients, the common clinical manifestation was headache, fever, vomiting and nausea. All of the ten CM patients were positive for CSF ink staining and nine of them were positive for CSF cryptococcal antigen latex agglutination test (titer 1:16–1:1024). Chest pain was the most obvious symptom in the patient with PC (GX0717). Chest CT showed a nodular shadow (0.6 cm in diameter) in the right lower lobe and multiple patchy shadow of the lungs; pathologic examination of the lung tissue biopsy demonstrated the cryptococcal yeast forms. Only one patient (GX0080) was previously diagnosed as systemic lupus erythematosus (SLE) and received corticosteroid treatment. Whereas, no significant immune abnormalities was detected in other patients.

Table 1. Epidemiological and clinical characteristics of eleven patients with Cryptococcus gattii species complex infections in Guangxi, southern China*.

Case no. Age,y/ gender Occupation Clinical syndrome Physical signs Specimen cultured Latex agglutination test Clinical diagnosis Treatment Outcome
GX0049 37/M Worker Convulsion, altered consciousness, limb weakness, fever Meningeal irritation and pathological reflex positive CSF 1:64 CM AMB(1275mg)+FLC(13.2g)+5FC(270g) Survived
GX0079 40/M Truck driver Headache, vomiting, blurred vision Neck stiffness CSF 1:256 CM Unknown Survived
GX0080 31/F Farmer Fever, headache, nausea, vomiting, chills Normal CSF 1:16 CM AMB(2035mg)+FLC(36.4g) Survived
GX0158 54/F Farmer Headache, nausea, vomiting, fever Normal CSF 1:128 CM AMB(2580mg)+FLC(22g)+5FC(299.5g) Survived
GX1622 29/M Farmer Headache, vomiting, fever, blurred vision Normal CSF 1:80 CM AMB(740mg)+FLC(8g) Survived
GX0104 30/M Farmer Headache, nausea, vomiting, fever Normal CSF 1:1024 CM AMB(1800mg)+FLC(39.6g)+5FC(52g) Survived
GX0105 29/F Unknown Headache, fever, dizzy, chills Neck stiffness, Kernig’s sign positive CSF 1:64 CM AMB(1625mg)+FLC(26.4g)+5FC(248g) Survived
GX0147 44/M Farmer Headache, fever, chills Neck stiffness CSF 1:1024 CM AMB(189mg)+FLC(5g)+5FC(30g) Died
GX0476 42/M Unknown Headache, fever, cough Normal CSF None CM Unknown Survived
GX0903 36/M Aquiculture Headache, dizzy, nausea, vomiting, fever Neck stiffness CSF 1:32 CM AMB(2200mg)+FLC(20.8g)+5FC(278g) Survived
GX0717 47/M Civil servant Chest pain, cough, expectoration Normal Lung tissue None PC AMB(140mg)+FLC(2.4g) Survived

*Cerebrospinal fluid, CSF; CM, Cryptococcal meningitis; PC, Pulmonary cryptococcosis

According to Infectious Diseases Society of America (IDSA) guidelines and China's expert consensus on the diagnosis and treatment of cryptococcal meningitis[36, 37], most of the patients have been significantly relieved after the cryptococcosis induction period treatment with combination therapy of two (AMB and FLC) or three (AMB, FLC and 5FC) antifungal drugs. Median cumulative dose and duration were 1625 mg (range 140–2580 mg) and 47 days (range 5–63 days) for AMB, 259 g (range 30–299.5 g) and 45.5 days (range 5–63 days) for 5FC, 20.8 g (range 2.4–39.6 g) and 50 days (range 6–66 days) for FLC. Even after the infection was treated and discharged from hospital, most patients continued the antifungal treatment with 0.2 g-0.4 g/day of FLC. Despite antifungal treatment, one patient died (GX0147) after giving up treatment because of no significant improvement. No patient had travel history outside China.

Identification of sequence type

MLST analysis of the eleven isolates indicated that five isolates were C. gattii s.s., and the other six isolates belonged to C. deuterogattii (Figs 1 and 2, Table 2). Five and three different sequence types (STs) were detected in C. gattii s.s. and C. deuterogattii, respectively; essentially all C. gattii s.s. isolates were genetically different and represented by a single isolate when MLST sequences were analyzed (Fig 1); sample GX0079 was quite divergent from the selected AFLP4/VGI strains. In contrast, C. deuterogattii isolates were divided into three major groups, with ST169 and ST129 represented by more than one isolate (Table 2).

Fig 1. Phylogenetic analysis of eleven C. gattii species complex.

Fig 1

Phylogenetic relationships inferred from a maximum likelihood analysis of CAP59, GPD1, LAC1, IGS1, PLB1, SOD1 and URA5 sequences of eleven C. gattii species complex from Guangxi, southern China (in blue) and 18 reference strains, covering the four major molecular types in C. gattii species complex. The branches with bootstrap support higher than 70% are shown.

Fig 2. Phylogenetic analysis of C. deuterogattii isolates.

Fig 2

The figure showing the relationships between the Chinese (strains of current investigation in red) and global C. deuterogattii strains inferred from the maximum likelihood analysis based on the combined ISHAM consensus MLST loci using MEGA7. Standard reference strains C. gattii s.s. (WM179), C. bacillisporus (WM161), C. tetragattii (WM779) and C. decagattii (IHEM14941) were used as outgroups. Epidemiologically significant isolates from the Pacific Northwest outbreaks were in blue. The branches with bootstrap support of more than 70% are indicated in bold.

Table 2. The STs and mating types of clinical Cryptococcus gattii species complex isolates in Guangxi, southern China*.

Strains Allele type ST Molecular type Mating type
CAP59 GPD1 IGS1 LAC1 PLB1 SOD1 URA5
GX0049 36 11 13 5 13 36 14 106 VGI α
GX0079 49 11 59 13 13 71 24 227 VGI α
GX0080 16 5 3 5 5 32 12 51 VGI α
GX0158 36 11 83 13 13 47 15 222 VGI α
GX1622 53 11 13 13 13 68 15 232 VGI α
GX0104 40 35 57 4 1 59 2 129 VGII α
GX0105 8 6 25 4 1 16 6 129 VGII α
GX0147 40 35 57 4 1 59 2 129 VGII α
GX0476 2 35 57 4 1 104 2 309 VGII α
GX0903 2 25 26 21 9 8 7 169 VGII α
GX0717 2 25 26 21 9 8 7 169 VGII α

*ST, sequence type

Genetic analysis of the Chinese and global C. deuterogattii isolates indicated that four Chinese isolates (GX0104, GX0105, GX0147 and GX0476) clustered closely with the C. deuterogattii AFLP6/VGII strains from Brazil (LMM293 and ILA3279), while the clinical isolates GX0903 and GX0717 clustered in a group containing C. deuterogattii AFLP6/VGII strains from Spain (CCA242OLD), Singapore (DF12341), the USA (B8973) and France (IP2003/125) (Fig 2). These isolates did not cluster with the highly virulent C. deuterogattii strains (AFLP6A/VGIIa R265 and AFLP6C/VGIIc A6M-R38) reported in the PNW outbreaks in Canada and the USA, but isolate GX0476 clustered in a group forming a sister relationship with the group harboring AFLP6C/VGIIc (A6M-R38) from Oregon, the USA.

Comparison of Chinese and global isolates

PCA (based on ISHAM-MLST) was also used to assess the genetic relationship between Chinese and global isolates (S1 Fig). Approximately 41.8% of the genetic variation can be explained in C. gattii s.s. (PC1 30.0%, PC2 11.8%) (S1A Fig), and 35% of the variation was explained in C. deuterogattii (PC1 17.9%, PC2 17.1%) (S1B Fig). The PCA did not group C. gattii species complex strains according to their origin, which was consistent with the results of the phylogenetic analysis (S1 Fig). Among the C. deuterogattii isolates, the four C. deuterogattii isolates appeared to be originated from South America.

Physiological characterization

All of the clinical isolates analyzed were MATα (Fig 3A). Based on the crossing experiment with JEC20 (AFLP2/VNIV), three C. deuterogattii strains (GX0104, GX0105 and GX0147) were able to undergo sexual reproduction in vitro, and basidia and basidiospores were formed during sexual reproduction (Fig 3B). Two C. deuterogattii isolates (GX0105 and GX0147) exhibited a weak mating response, with only a few filaments, basidia and basidiospores developed.

Fig 3.

Fig 3

(A) Simultaneous amplification of all clinical strains and two reference strains using primers targeting the MATα and MATa genes and (B) mating reactions of the isolates showing typical basidia and basidiospores. (A) Reference strains: R265 (MATα, AFLP6A/VGIIa) and JEC20 (MATa, AFLP2/VNIV). Clinical isolates were all MATα. (B) Sexual reproduction cultures including hyphae, basidia and basidiospores, incubated on V8 agar (pH = 5) at 25°C for 2 weeks in the dark.

The tested clinical isolates produced melanin at both 30°C and 37°C, while most strains had greater melanin production at 30°C than at 37°C (S2A Fig). Two C. deuterogattii strains (GX0104 and GX0903) appeared to have greater melanin production than the reference strain (AFLP6A/VGIIa R265) at 37°C. Moreover, these clinical strains produced capsule of different size in vitro (S2B Fig); however, our data revealed no significant difference (p > 0.05) in the capsule size between GX0104 and R265 (S2C Fig).

Antifungal drug susceptibility

As the MICs shown in Table 3, none of the strains demonstrated resistance to the antifungal drugs. The susceptibility ranges of the five C. gattii s.s. isolates were 1–4 μg/mL for FLC, 0.125–0.5 μg/mL for 5FC, 0.25–0.5 μg/mL for AMB, 0.125–0.25 μg/mL for ITC, 0.0156–0.125 μg/mL for VOR, 0.0156–0.25 μg/mL for POS, and 0.0078–0.125 μg/mL for ISA. For the six C. deuterogattii isolates, the susceptibility ranges were 1–16 μg/mL for FLC, 0.0625–1 μg/mL for 5FC, 0.25–1 μg/mL for AMB, 0.0625–0.25 μg/mL for ITC, 0.0156–0.125 μg/mL for VOR, 0.0156–0.25 μg/mL for POS, and 0.0078–0.125 μg/mL for ISA. According to the clinical efficacy, combination of two or three drugs in AMB, FLC, and 5FC were effective for treatment. There were no significant differences between the C. gattii s.s. and C. deuterogattii isolates against these seven antifungal drugs (p > 0.05).

Table 3. Minimal inhibitory concentrations (MICs) of all the Cryptococcus gattii species complex isolates in Guangxi, southern China*.

Strains Minimal inhibitory concentration (μg/mL)
FLC 5FC AMB ITC VOR POS ISA
GX0049 1 0.5 0.25 0.125 0.0313 0.0625 0.0313
GX0079 2 0.125 0.5 0.25 0.0625 0.0625 0.0313
GX0080 1 0.25 0.5 0.25 0.0156 0.0156 0.0078
GX0158 2 0.125 0.25 0.125 0.0313 0.0625 0.0313
GX1622 4 0.5 0.5 0.25 0.125 0.25 0.125
GX0104 1 0.0625 1 0.0625 0.0156 0.0156 0.0078
GX0105 4 0.5 0.5 0.25 0.0625 0.0625 0.0625
GX0147 4 1 0.5 0.25 0.0625 0.0625 0.0625
GX0476 16 0.5 0.5 0.125 0.0625 0.25 0.125
GX0903 2 0.25 0.25 0.25 0.0625 0.125 0.125
GX0717 4 0.5 0.5 0.25 0.125 0.125 0.125
MIC range 1–16 0.125–1 0.25–1 0.0625–0.25 0.0156–0.125 0.0156–0.25 0.0078–0.125
MIC50 2 0.25 0.5 0.25 0.0625 0.0625 0.0625
MIC90 4 0.5 0.5 0.25 0.125 0.25 0.125
Geometric mean 2.5733 0.2836 0.4695 0.1824 0.0486 0.0709 0.0456

* FLC, fluconazole; 5FC, fluorocytosine; AMB, amphotericin B; ITC, itraconazole; VOR, voriconazole; POS, posaconazole; ISA, isavuconazole; MIC, minimal inhibitory concentration

Discussion

Our current study showed that C. gattii species complex infection in Guangxi, southern China were caused by both C. gattii s.s. (AFLP4/VGI) and C. deuterogattii (AFLP6/VGII), with different MLST genotypes and virulence factor characteristics. Similar pattern has also been reported in other countries such as Canada, Brazil, Australia and the USA[2931]. Although C. deuterogattii in this study was genetically indistinguishable from the outbreak genotypes AFLP6A/VGIIa (R265) and AFLP6C/VGIIc (A6M-R38), they were related to other global C. deuterogattii isolates isolated from Brazil (LMM293 and ILA3279), Singapore (DF12341) and Spain (CCA242OLD). C. deuterogattii strains are genetically diverse, and there was great genotypic variability among C. deuterogattii subtypes (AFLP6A/VGIIa and AFLP6C/VGIIc), particularly those in Brazil[38]. Despite the small sample size in this study, most Chinese clinical strains were genetically diverse, with eight STs reported. The variability could be due to special ecological interactions, adaptations and evolutionary mechanisms. Cryptococcus species are able to adapt to different ecological niches and temperatures and they can adapt within the host and environment through microevolution. The Cryptococcus genome is also dynamic in its plasticity[39].

In the present study, we found that all isolates harbored the MATα gene at the mating type locus, and three of six C. deuterogattii strains (GX0104, GX0105 and GX0147) were able to undergo sexual reproduction, thus recombination could be one of the causes for the genetic diversity among the Chinese C. deuterogattii strains. Moreover, offspring produced by sexual reproduction/recombination may be able to adapt to and colonize new environment[40, 41]. In the mating assays of eleven clinical strains with the opposite mating type strains (AFLP6/VGII, AFLP2/VNIV and AFLP1/VNI), only the cross of AFLP6/VGII × AFLP2/VNIV exhibited mating response. Hybridization between the two cryptococcal species complexes seems to be a much rarer event in nature compared to hybridization between C. neoformans species complex lineages[42]. Even though the mating between the parental lineages can be induced in the laboratory, their progenies were not commonly reported in the environmental and clinical samples[43]. Recombination may also occur between the AFLP4/VGI and AFLP6/VGII isolates in China because previous research has highlighted possible gene transfer (introgression) between different C. gattii s.l. clades, either bisexually or unisexually, thereby contributing to the production of virulence subtypes[41, 44]. Sex can contribute to de novo diversity[45], which may be the reason for the diversity in the MLST analysis of clinical C. deuterogattii isolates. In addition, the capacity for mating could generate additional infectious propagules, leading to increased exposure and, ultimately, an enhanced infection rate[31].

Clinical data from this study showed that almost all patients had no obvious immunodeficiency, except one patient with SLE, which was consistent with the fact that the C. gattii species complex causes infection in immunocompetent hosts[11]. Most strains in Guangxi, southern China had the capabilities to produce melanin and capsule, as well as to undergo sexual reproduction. These are major virulence factors known to contribute to Cryptococcus pathogenesis and have been well characterized in C. gattii species complex. However, very few past studies have investigated these virulence factors in Chinese strains. Our data showed that most Chinese strains, similar to the reference outbreak strain R265 from Canada, have the abilities to be virulent. However, animal model studies need to be performed in order to establish their virulence levels to human hosts and whether their virulence would be comparable to the highly virulent outbreak (R265) and less virulent strain (R272) from the PNW[29].

Most patients significantly relieved after combination therapy while one patient (GX0147) passed away after giving up treatment because of no significant improvement. However, antifungal susceptibility testing indicated that strains in this study are not resistant to antifungal drugs because their MIC values were within the susceptible range[3335]. Therefore, although none of the strains demonstrated resistance to these drugs, other factors may complicate the therapeutic outcomes of these patients.

Cryptococcus can be dispersed through the movement of trees and wood products, air currents, water currents, and biotic sources, such as birds, animals and insects[13]. Unlike C. neoformans species complex, which is found commonly in soils contaminated with wild and pet bird droppings, especially pigeon droppings, C. gattii species complex prefer to grow within and underneath moist bark, tree hollows, tree trunks and in soil debris near specific trees that are often found in nature (including Eucalyptus, Azadirachta, Castanopsis, Prunus dulcis, Pinus canariensis and Pseudotsuga menziesii)[46]. The evidence for C. gattii species complex dispersal by wind and air currents is limited, but fungal isolations from air samples have been obtained around positive trees in Canada and India[13]. “Guangxi Autonomous Region” belongs to southern China and lays on the southeastern corner of the Yunnan-Guizhou Plateau, situated from 20º54′N to 26º24′N and from 104º26′E to 112º04′E. This region borders Vietnam to the southwest and is surrounded by Guangdong, Guizhou, Yunnan, and Hunan Provinces in China. The region has a terraced topography sloping from the northwest to the southeast, with hilly land constituting 85% of its total area and plains constituting 15%. The region has a subtropical humid monsoon climate, with average daily temperatures of 16°C to 23°C. The rainy season lasts from April until September, with an annual rainfall of 1500 mm to 2000 mm[47]. The warm, subtropical monsoon climate in Guangxi is also favorable for the growth and reproduction of the C. gattii species complex. In this study, most patients were farmers in rural areas and had a history of contact with above plants and soil, especially Eucalyptus, but without travel record to the epidemic areas such as the PNW region, or the endemic area of C. gattii species complex such as South America and Australia, indicating that their cryptococcosis infection was spread through contact with the local environment. Frequent and regular contact with the natural environment may explain how these patients acquired the infections[48]. The genetic variabilities of Chinese C. gattii species complex members also suggested the possibility of multiple independent origins. Combined with the phylogenetic analysis of this study, some Chinese strains were related to those from Brazil. Therefore, this may be traced to the wood/seedlings imported from elsewhere, such as South America and Australia[49]. However, additional isolation and investigation of the C. gattii species complex from the environment such as trees, soil and wild animals is necessary to establish the environment as the source of infection in Guangxi Province, China.

Cryptococcosis infections caused by the C. gattii species complex are relatively rare in comparison to those caused by the C. neoformans species complex (11.4% versus 88.6%)[15]; however, recent studies have indicated that they may be mis- or underdiagnosed globally[50]. Similarly, the number of C. gattii species complex infections in China may be underestimated. Compared with the data from other provinces in China[14, 51], the rate of C. gattii species complex infection in Guangxi was approximately 9% (11/120), and most infection were caused by C. deuterogattii; however, additional epidemiological and surveillance studies are required.

There are several limitations of this study. First, a small number of patients were included in the study. Second, due to the retrospective nature of study, there was no long-term follow-up assessment of these patients, which have led to some missing data. Third, the level of virulence among these strains still needs further study on animal models. Fourth, environmental isolates should be sampled to assess the relationship of environmental niche for C. gattii species complex in this area. Thus, performing a prospective study with a larger study population are expected to elucidate the population structure and mechanisms of C. gattii species complex. Presently, we are in collaboration with other hospitals to carry out regional surveillance of Cryptococcus infections in China.

In summary, the C. gattii species complex should receive substantial attention in China due to its genetic variability, ability to infect immunocompetent hosts and propensity to undergo sexual reproduction and cause outbreaks, even the number of infections was low. Given that all patients in this investigation may have acquired the infection from nature, the environmental distribution, genetic variability and virulence level of the C. gattii species complex should not be underestimated. At the same time, we strive to improve the differential diagnosis of the C. gattii species complex in the early stages of infection and to use targeted treatment programs to reduce the risk of infection.

Supporting information

S1 Fig. Genetic relationships of C. gattii s.s.

(a) and C. deuterogattii (b) between Guangxi, southern China, and global isolates illustrated by principal component analysis (PCA).

(PDF)

S2 Fig

(a)Visual analysis of melanin production after fungal growth on caffeic acid agar at 30°C and 37°C for three days. (b) Polysaccharide capsule surrounding the cells of C. deuterogattii isolates under microscopy. (c) Capsule production test in RPMI-1640 with 5% CO2 at 37°C representing the average capsule-capsule:cell wall-cell wall ratio of the six clinical isolates and the reference strain (AFLP6A/VGIIa R265). (X400, p < 0.001) (error bars ± SE = 2 SE).

(PDF)

Acknowledgments

We acknowledge all microbiologists at the First Affiliated Hospital of Guangxi Medical University for technical assistance and the isolation of Cryptococcus cultures. We also thank Ferry Hagen (Westerdijk Fungal Biodiversity Institute, the Netherlands) for discussion and sharing the sequence alignment of global C. deuterogattii (AFLP6/VGII) isolates.

Data Availability

MLST nucleotide sequences for the eleven clinical isolates determined in this study have been deposited in the GenBank nucleotide sequence database under accession numbers MK344035-MK344111.

Funding Statement

This study was supported by grants from the National Natural Science Foundation of China (Nos. 81571971 and 81271804) and the Natural Science Foundation of Guangxi Province of China (2017GXNSFAA198004, AB18221017 and 2018GXNSFAA294090). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

References

  • 1.Bielska E, May RC. What makes Cryptococcus gattii a pathogen? FEMS yeast research. 2016;16(1):fov106 10.1093/femsyr/fov106 . [DOI] [PubMed] [Google Scholar]
  • 2.Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, et al. Cryptococcus neoformans and Cryptococcus gattii, the Etiologic Agents of Cryptococcosis. Cold Spring Harb Perspect Med. 2014;4(7):a019760 10.1101/cshperspect.a019760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chen SC, Meyer W, Sorrell TC. Cryptococcus gattii Infections. Clinical microbiology reviews. 2014;27(4):980–1024. 10.1128/CMR.00126-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chen Y, Frazzitta AE, Litvintseva AP, Fang C, Mitchell TG, Springer DJ, et al. Next generation multilocus sequence typing (NGMLST) and the analytical software program MLSTEZ enable efficient, cost-effective, high-throughput, multilocus sequencing typing. Fungal genetics and biology: FG & B. 2015;75:64–71. 10.1016/j.fgb.2015.01.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Medical mycology. 2009;47(6):561–70. 10.1080/13693780902953886 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Liu XZ, Wang QM, Theelen B, Groenewald M, Bai FY, Boekhout T. Phylogeny of tremellomycetous yeasts and related dimorphic and filamentous basidiomycetes reconstructed from multiple gene sequence analyses. Studies in mycology. 2015;81:1–26. 10.1016/j.simyco.2015.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal genetics and biology: FG & B. 2015;78:16–48. 10.1016/j.fgb.2015.02.009 . [DOI] [PubMed] [Google Scholar]
  • 8.Liu XZ, Wang QM, Goker M, Groenewald M, Kachalkin AV, Lumbsch HT, et al. Towards an integrated phylogenetic classification of the Tremellomycetes. Studies in mycology. 2015;81:85–147. 10.1016/j.simyco.2015.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proceedings of the National Academy of Sciences of the United States of America. 2004;101(49):17258–63. 10.1073/pnas.0402981101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerging infectious diseases. 2009;15(8):1185–91. 10.3201/eid1508.081384 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Herkert PF, Hagen F, Pinheiro RL, Muro MD, Meis JF, Queiroz-Telles F. Ecoepidemiology of Cryptococcus gattii in Developing Countries. Journal of fungi. 2017;3(4). 10.3390/jof3040062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hagen F, Chowdhary A, Prakash A, Yntema JB, Meis JF. Molecular characterization of Cryptococcus gattii genotype AFLP6/VGII isolated from woody debris of divi-divi (Caesalpinia coriaria), Bonaire, Dutch Caribbean. Revista iberoamericana de micologia. 2014;31(3):193–6. 10.1016/j.riam.2013.10.007 . [DOI] [PubMed] [Google Scholar]
  • 13.Springer DJ, Chaturvedi V. Projecting Global Occurrence of Cryptococcus gattii. Emerging infectious diseases. 2010;16(1):14–20. 10.3201/eid1601.090369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chen M, Pan WH, Boekhout T. Cryptococcus gattii infections in China: extent of the problem? Chinese Medical Journal. 2013;126(2):203–5. 10.3760/cma.j.issn.0366-6999.20122407 [DOI] [PubMed] [Google Scholar]
  • 15.Cogliati M. Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types. Scientifica. 2013;2013:675213 10.1155/2013/675213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Okamoto K, Hatakeyama S, Itoyama S, Nukui Y, Yoshino Y, Kitazawa T, et al. Cryptococcus gattii Genotype VGIIa Infection in Man, Japan, 2007. Emerging infectious diseases. 2010;16(7):1155–7. 10.3201/eid1607.100106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Feng X, Yao Z, Ren D, Liao W, Wu J. Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients. FEMS yeast research. 2008;8(6):930–8. 10.1111/j.1567-1364.2008.00422.x . [DOI] [PubMed] [Google Scholar]
  • 18.Wu SY, Lei Y, Kang M, Xiao YL, Chen ZX. Molecular characterisation of clinical Cryptococcus neoformans and Cryptococcus gattii isolates from Sichuan province, China. Mycoses. 2015;58(5):280–7. 10.1111/myc.12312 . [DOI] [PubMed] [Google Scholar]
  • 19.Dou HT, Xu YC, Wang HZ, Li TS. Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii in China between 2007 and 2013 using multilocus sequence typing and the DiversiLab system. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2015;34(4):753–62. 10.1007/s10096-014-2289-2 . [DOI] [PubMed] [Google Scholar]
  • 20.Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL, Wengenack NL. Identification of Cryptococcus gattii by Use of L-Canavanine Glycine Bromothymol Blue Medium and DNA Sequencing. Journal of clinical microbiology. 2009;47(11):3669–72. 10.1128/JCM.01072-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Herkert PF, Hagen F, de Oliveira Salvador GL, Gomes RR, Ferreira MS, Vicente VA, et al. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2016;35(11):1803–10. 10.1007/s10096-016-2731-8 . [DOI] [PubMed] [Google Scholar]
  • 22.Kinne J, Joseph M, Wernery U, Nogradi N, Hagen F. Disseminated Cryptococcus deuterogattii (AFLP6/VGII) infection in an Arabian horse from Dubai, United Arab Emirates. Revista iberoamericana de micologia. 2017;34(4):229–32. 10.1016/j.riam.2017.02.007 . [DOI] [PubMed] [Google Scholar]
  • 23.Souto AC, Bonfietti LX, Ferreira-Paim K, Trilles L, Martins M, Ribeiro-Alves M, et al. Population Genetic Analysis Reveals a High Genetic Diversity in the Brazilian Cryptococcus gattii VGII Population and Shifts the Global Origin from the Amazon Rainforest to the Semi-arid Desert in the Northeast of Brazil. PLoS Negl Trop Dis. 2016;10(8):e0004885 10.1371/journal.pntd.0004885 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Molecular biology and evolution. 2016;33(7):1870–4. 10.1093/molbev/msw054 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Price MN, Dehal PS, Arkin AP. FastTree 2 –Approximately Maximum-Likelihood Trees for Large Alignments. PLoS One. 2010;5(3):e9490 10.1371/journal.pone.0009490 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rocha DFS, Cruz KS, Santos C, Menescal LSF, Neto J, Pinheiro SB, et al. MLST reveals a clonal population structure for Cryptococcus neoformans molecular type VNI isolates from clinical sources in Amazonas, Northern-Brazil. PLoS One. 2018;13(6):e0197841 10.1371/journal.pone.0197841 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jombart T. adegenet: a R package for the multivariate analysis of genetic markers. Bioinformatics. 2008;24(11):1403–5. 10.1093/bioinformatics/btn129 . [DOI] [PubMed] [Google Scholar]
  • 28.S C, B R, J F, CM M, BL W, V. C. Direct PCR of Cryptococcus neoformans MATɑ and MATa Pheromones To Determine Mating Type, Ploidy, and Variety: a Tool for Epidemiological and Molecular Pathogenesis Studies. Journal of clinical microbiology. 2000;38(5):2007–9. 10.1128/JCM.38.5.2007-2009.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ngamskulrungroj P, Price J, Sorrell T, Perfect JR, Meyer W. Cryptococcus gattii Virulence Composite: Candidate Genes Revealed by Microarray Analysis of High and Less Virulent Vancouver Island Outbreak Strains. PLoS One. 2011;6(1):e16076 10.1371/journal.pone.0016076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Barcellos VA, Martins LMS, Fontes ACL, Reuwsaat JCV, Squizani ED, de Sousa Araujo GR, et al. Genotypic and Phenotypic Diversity of Cryptococcus gattii VGII Clinical Isolates and Its Impact on Virulence. Frontiers in microbiology. 2018;9:132 10.3389/fmicb.2018.00132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ngamskulrungroj P, Serena C, Gilgado F, Malik R, Meyer W. Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clinical Microbiology and Infection. 2011;17(2):251–8. 10.1111/j.1469-0691.2010.03222.x [DOI] [PubMed] [Google Scholar]
  • 32.Hong N, Chen M, Xu N, Al-Hatmi AMS, Zhang C, Pan WH, et al. Genotypic diversity and antifungal susceptibility of Cryptococcus neoformans isolates from paediatric patients in China. Mycoses. 2019;62(2):171–80. 10.1111/myc.12863 . [DOI] [PubMed] [Google Scholar]
  • 33.Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, et al. Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine. Antimicrobial agents and chemotherapy. 2012;56(6):3107–13. 10.1128/AAC.06252-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole. Antimicrobial agents and chemotherapy. 2012;56(11):5898–906. 10.1128/AAC.01115-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, et al. Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method. Antimicrobial agents and chemotherapy. 2015;59(1):666–8. 10.1128/AAC.04055-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2010;50(3):291–322. 10.1086/649858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Liu ZY, Wang GQ, Zhu LP, Lv XJ, Zhang QQ, Yu YS, et al. Expert consensus on the diagnosis and treatment of cryptococcal meningitis. Chinese Journal of Internal Medicine. 2018;57(5):317–23. 10.3760/cma.j.issn.0578-1426.2018.05.003 [DOI] [PubMed] [Google Scholar]
  • 38.Lockhart SR, Iqbal N, Harris JR, Grossman NT, DeBess E, Wohrle R, et al. Cryptococcus gattii in the United States: Genotypic Diversity of Human and Veterinary Isolates. PLoS One. 2013;8(9):e74737 10.1371/journal.pone.0074737 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Chen Y, Farrer RA, Giamberardino C, Sakthikumar S, Jones A, Yang T, et al. Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii. mBio. 2017;8(2):e00166–17. 10.1128/mBio.00166-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Maruyama FH, de Paula DAJ, Menezes IG, Favalessa OC, Hahn RC, de Almeida A, et al. Genetic Diversity of the Cryptococcus gattii Species Complex in Mato Grosso State, Brazil. Mycopathologia. 2019;184(1):45–51. 10.1007/s11046-018-0313-2 . [DOI] [PubMed] [Google Scholar]
  • 41.Billmyre RB, Croll D, Li W, Mieczkowski P, Carter DA, Cuomo CA, et al. Highly Recombinant VGII Cryptococcus gattii Population Develops Clonal Outbreak Clusters through both Sexual Macroevolution and Asexual Microevolution. mBio. 2014;5(4):e01494–14. 10.1128/mBio.01494-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Samarasinghe H, Xu J. Hybrids and hybridization in the Cryptococcus neoformans and Cryptococcus gattii species complexes. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2018;66:245–55. 10.1016/j.meegid.2018.10.011 . [DOI] [PubMed] [Google Scholar]
  • 43.Samarasinghe H, You M, Jenkinson TS, Xu J, James TY. Hybridization Facilitates Adaptive Evolution in Two Major Fungal Pathogens. Genes. 2020;11(1). 10.3390/genes11010101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Engelthaler DM, Hicks ND, Gillece JD, Roe CC, Schupp JM, Driebe EM, et al. Cryptococcus gattii in North American Pacific Northwest: Whole-Population Genome Analysis Provides Insights into Species Evolution and Dispersal. mBio. 2014;5(4):e01464–14. 10.1128/mBio.01464-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Fu C, Sun S, Billmyre RB, Roach KC, Heitman J. Unisexual versus bisexual mating in Cryptococcus neoformans: Consequences and biological impacts. Fungal genetics and biology: FG & B. 2015;78:65–75. 10.1016/j.fgb.2014.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Diaz JH. The Disease Ecology, Epidemiology, Clinical Manifestations, and Management of Emerging Cryptococcus gattii Complex Infections. Wilderness & environmental medicine. 2020;31(1):101–9. 10.1016/j.wem.2019.10.004 . [DOI] [PubMed] [Google Scholar]
  • 47.Cao C, Liang L, Wang W, Luo H, Huang S, Liu D, et al. Common reservoirs for Penicillium marneffei infection in humans and rodents, China. Emerging infectious diseases. 2011;17(2):209–14. 10.3201/eid1702.100718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K. Cryptococcus: from environmental saprophyte to global pathogen. Nature reviews Microbiology. 2016;14(2):106–17. 10.1038/nrmicro.2015.6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Huang GQ, Zhao QG. The history, status quo, ecological problems and countermeasures of Eucalyptus plantations in Guangxi. Acta Ecologica Sinica. 2014;34(18):5142–52. [Google Scholar]
  • 50.Tintelnot K, Hagen F, Han CO, Seibold M, Rickerts V, Boekhout T. Pitfalls in Serological Diagnosis of Cryptococcus gattii Infections. Medical mycology. 2015;53(8):874–9. 10.1093/mmy/myv061 . [DOI] [PubMed] [Google Scholar]
  • 51.Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal genetics and biology: FG & B. 2015;78(2015):7–15. 10.1016/j.fgb.2014.10.017 . [DOI] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0008493.r001

Decision Letter 0

Todd B Reynolds, Nelesh Premapragasan Govender

10 Mar 2020

Dear Pro. cao,

Thank you very much for submitting your manuscript "Emerging Cryptococcus gattii species complex infection in south China" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

Additional editor comments: 120 clinical isolates are mentioned as the “population” from which these 11 strains were drawn. Were all consecutive cryptococcal isolates (cultured from patients at First Affiliated Hospital of Guangxi Medical University) stored for study purposes between 2014-2018? If not, please specify this. Provide information on the clinical source (specimen type) and patient characteristics for all 120 isolates, if this is possible. What does “the outer court treatment” in Table 1 refer to? Please summarise the main limitations of this study in the discussion section.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Nelesh P. Govender

Guest Editor

PLOS Neglected Tropical Diseases

Todd Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Editor: 120 clinical isolates are mentioned as the “population” from which these 11 strains were drawn. Were all consecutive cryptococcal isolates (cultured from patients at First Affiliated Hospital of Guangxi Medical University) stored for study purposes between 2014-2018? If not, please specify this. Provide information on the clinical source (specimen type) and patient characteristics for all 120 isolates, if this is possible. What does “the outer court treatment” in Table 1 refer to? Please summarise the main limitations of this study in the discussion section.

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: The objectives are clear with the appropriate design. The screening of 120 clinical strains between 2014-2018 by L-concanavanine-glycine-bromthymol blue (CGB) medium showed 11 Cryptococcus gattii species complex from Non-HIV patients in South China. Five of C. gattii ss (and six of C. deuterogattii (AFLP6A/VGIIa) Mating and susceptibility test against 7 common antifungal agents were investigated. The genetic variation and phylogenetic tree using MLST information were analyzed fertility

However:

1. The first sentence of materials and methods: 120 clinical strains were collected....... It is not clear whether 120 clinical strains of which group of organisms they recruited for CGB screening.

2. The demography, association diseases, antifungal agents profiles, genetic variation, and phylogenetic trees were analyzed based on 11 isolates after screening of 120 isolates (might be suspected Cryptococcus spp.??).

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: - Table 1: -- More detail of clinical syndrome and temp. of fever should be mentioned to let the readers learn from experience of the authors and any other laboratory diagnosis was examined or not, ie: cryptococcal antigen.

-- Environment contact : Eucalyptus and pigeon. Actually Cryptococcus's habitat is not only the Eucalyptus and pigeon. It can be the tree bark, the hollow of big trees and other avian exclude from pigeon. Thus, isn't it leads the readers to misunderstand the environment niche.

- Genetic variation and phylogenetic trees based on the 7 loci-MSLT performing were analyzed and the result showed the association with the global isolates.

- Fertility was detected. Capsule sIze and melanin pigment formation were all comparable to standard strains.

- The 7 antifungal agents profiles against these 11 C. gattii cpx according to the CLSI protocol were investigated.

- The antifungal drug dosage and duration of treatment are other significance factors to let the readers get some information for the survivals and decease.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: This authors concluded that the mating α C. gattii complex were isolated from clinical specimens in South China between 2014-2018 and all these emerging 11 isolates, (10%, if 120 isolates were Cryptococcus spp.) are all susceptible to antifungal agents. The small genetic variation, 8STs, in their isolates were found and related to the reported strains from other countries. The distribution of C. gattii cpx. in this area might due to the capability of sexual reproduction. The authors proposed the future study to confirm the virulence in animal model.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: Minor revision: - as mentioned above regarding more clinical symptom, antifungal dosage,

- the original group in the CGB screening, more explanation about the environment niche, not only Eucalyptus tree,..

- Clinical manifestation and/or diagnosis should provide more information, ie: GX0717 chest pain and specimens : Lung tissue. This information does not provide any more info. It is just like common things. How the X-ray? How is

- The best condition for Laccase gene: melanin pigment formation will be 30C is already the theory so I donot think this will give any benefit for this experiment.

-The limitation of sample should be focused in discussion.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: Dear Editor

The manuscript entitled “Emerging Cryptococcus gattii species complex infection in south China” by Huang et al, presented the link between C. deuterogattii isolates from south China and those from Brazil, Spain, Singapore, USA and France. Although the number of isolates in this study was quite small (N=11), this report would trigger some interesting points for further investigation to see how C. gattii complex spreads worldwide. There are some comments for the manuscript.

1. For the mating experiment, why the authors performed the experiment using JEC20 to mate with C. gattii complex. The JEC20 is C. neoformans serotype D, not C. gattii complex. The authors should use C. gattii complex MATa to do the experiment to make it more convincing. In the discussion Line 318-322, the authors mentioned that sexual reproduction could cause genetic diversity from these results. Is it usual that C. gattii mate with C. neoformans in the environment?

2. The capsule and melanin production in these virulent strains is not unexpected as those virulent factors are well-known. Therefore, these data did not add anything new. To make it more convincing, the capsule and melanin experiments need a non-virulent (environmental) C. gattii strain as a negative control (in addition to R265 strain). In this case, R272 (environmental C. gattii isolate) may be used as a control to show that it produces less capsule and melanin that the China isolates.

3. Line284 “……our data revealed no significant different (p < 0.01) in ….”. This is confusing why it was not significant as the p value was < 0.01.

4. The authors should discuss why they use triple drug combination to treat C. gattii infection (amphotericin B plus fluconazole plus flucytosine). Is there any guideline in China recommend this combination therapy?

Reviewer #2: (No Response)

Reviewer #3: The authors tried to provide the emerging information of C. gattii complex in 2014-2018 in South China and demonstrated how significant they are thru the virulence factors, mating, capsule formation, melanin formation. In addition, the genetic variation of their strains are associate with the global strains which imply that this is not the result from recombination inside South China.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods

Attachment

Submitted filename: 02-13-2020 PLoSNTD article review Huang et al.docx

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0008493.r003

Decision Letter 1

Todd B Reynolds

17 Jun 2020

Dear Pro. cao,

We are pleased to inform you that your manuscript 'Emerging Cryptococcus gattii species complex infection in Guangxi, southern China' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted, you will need to complete some formatting changes, but you will  will receive information on these formatting changes in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Todd B. Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases

Todd Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: The content in materials and methods are corresponded to the listed questions except the grammar of the verb after the data shouldn't be "were" not was (L173). The authors revised and provided the clear image of how the isolates derived from and how to proof the isolates which the experiments used the standard methods. Multilocus sequencing typing (MLST), one of the standard and verified tool to analyse the new sequence types were performed . However, the authors should provide the full name before write the short name (L.196). The ethical concern was clarified.

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: The authors edited the results as comments, making the clear results. Each issue was clarified and finally the authors could show the new STs and characterised Cryptococcus gattii in Guangxi, southern China and showed how these eleven isolates related to Cryptococcus in other locations. Their antifungal profiles and demography of patients were laborated.

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: The summary and the limitations were explained.

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: Two points were already pointed out: grammatical error and the full name.

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: Dear editor,

The authors have explained clearly in the "response to reviewers" and the revised manuscript. The data they presented would interest the readers. I have no further question.

Regards,

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0008493.r004

Acceptance letter

Todd B Reynolds

10 Aug 2020

Dear Pro. cao,

We are delighted to inform you that your manuscript, "Emerging Cryptococcus gattii species complex infections in Guangxi, southern China," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Genetic relationships of C. gattii s.s.

    (a) and C. deuterogattii (b) between Guangxi, southern China, and global isolates illustrated by principal component analysis (PCA).

    (PDF)

    S2 Fig

    (a)Visual analysis of melanin production after fungal growth on caffeic acid agar at 30°C and 37°C for three days. (b) Polysaccharide capsule surrounding the cells of C. deuterogattii isolates under microscopy. (c) Capsule production test in RPMI-1640 with 5% CO2 at 37°C representing the average capsule-capsule:cell wall-cell wall ratio of the six clinical isolates and the reference strain (AFLP6A/VGIIa R265). (X400, p < 0.001) (error bars ± SE = 2 SE).

    (PDF)

    Attachment

    Submitted filename: 02-13-2020 PLoSNTD article review Huang et al.docx

    Attachment

    Submitted filename: Responses to editor and reviewer.docx

    Data Availability Statement

    MLST nucleotide sequences for the eleven clinical isolates determined in this study have been deposited in the GenBank nucleotide sequence database under accession numbers MK344035-MK344111.


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES